- StageZero Life Sciences Ltd. detects early stage cancer and multiple disease states through blood examination screening tests. They also do COVID-19 testing.
- One in 5 men and one in 6 women worldwide develop cancer during their lifetime, with 9.6 million global deaths from cancer in 2018.
- StageZero's flagship revolutionary product 'Aristotle' tests for 10 common cancers in one test and is set to be released Q1 2020.
- Clarus Securities says "Stage Zero Life Sciences could achieve a billion dollar market cap." StageZero has a price target of C$4.00 representing a potential 5.5x upside.
For further details see:
An Update On Stage Zero Life Sciences As Their Aristotle Cancer Screen Gets Set To Launch